American College of Cardiology 2011

Controlled-Release Phentermine/Topiramate Produces and Maintains Significant Weight Loss and CV Risk Reduction Over 2 Years

Treatment with a low-dose, controlled-release combination of phentermine and topiramate (PHEN/TPM CR) resulted in significant weight loss and improvements in cardiovascular risk factors in a comorbid population of overweight and obese subjects in two consecutive clinical trials (CONQUER and SEQUEL) reported on at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Intensive Atorvastatin Therapy Reduces CV Events in Patients with Dyslipidemia and CHD with Chronic Kidney Disease

The use of intensive atorvastatin therapy in patients with more advanced chronic kidney disease (CKD) provides statistically significant reductions in cardiovascular events (CVE), results of a retrospective analysis showed at a presentation at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session.

Clopidogrel Pretreatment Associated with Improved Outcomes for Patients Undergoing Primary PCI for STEMI

At ACC.11, the American College of Cardiology’s 60th Annual Scientific Sessions, study investigators reported that clopidogrel pretreatment was associated with a significant reduction in platelet ADP induced aggregation in primary percutaneous intervention (PPCI) for STEMI, which was associated with improved myocardial reperfusion.

Combined Therapy of Ezetimibe/Simvastatin plus Extended-Release Niacin Helps Hyperlipidemic Patients Reach Lipid Goals

Data presented at ACC.11, the American College of Cardiology’s 60th Annual Scientific Session, demonstrated that combination ezetimibe/simvastatin + extended-release niacin (E/S+N) is an effective therapeutic option for reaching lipid goals in patients with hyperlipidemia, specifically as regards target LDL-C, non-HDL-C, and apoB levels.